Oncomine Lung cfTNA Cancer Panel: Advanced Lung Cancer Detection
Comprehensive Introduction to Lung Cancer Genetic Testing
The Oncomine Lung cfTNA Cancer Panel represents a groundbreaking advancement in lung cancer diagnostics, offering a non-invasive approach to detecting and monitoring lung cancer through circulating tumor nucleic acids (cfTNA). This innovative test utilizes next-generation sequencing (NGS) technology to analyze genetic material shed by tumor cells into the bloodstream, providing comprehensive molecular profiling without the need for invasive tissue biopsies.
Lung cancer remains one of the most prevalent and deadly cancers worldwide, with early detection and personalized treatment being crucial for improved outcomes. The Oncomine Lung cfTNA Cancer Panel addresses this critical need by enabling healthcare providers to make informed treatment decisions based on the specific genetic characteristics of each patient’s cancer.
What the Test Measures and Detects
The Oncomine Lung cfTNA Cancer Panel employs sophisticated NGS technology to detect and analyze multiple genetic biomarkers associated with lung cancer:
- EGFR Mutations: Identifies epidermal growth factor receptor mutations that respond to targeted therapies
- ALK Rearrangements: Detects anaplastic lymphoma kinase fusions for specific inhibitor treatments
- ROS1 Fusions: Identifies ROS proto-oncogene 1 rearrangements
- BRAF Mutations: Detects B-Raf proto-oncogene variations
- KRAS Mutations: Identifies Kirsten rat sarcoma viral oncogene homolog changes
- MET Amplifications: Detects mesenchymal-epithelial transition gene amplifications
- RET Fusions: Identifies rearranged during transfection gene rearrangements
- NTRK Fusions: Detects neurotrophic tyrosine receptor kinase gene fusions
Who Should Consider This Test
The Oncomine Lung cfTNA Cancer Panel is recommended for individuals experiencing:
- Persistent cough or coughing up blood
- Unexplained weight loss and fatigue
- Chest pain or shortness of breath
- Hoarseness or recurrent respiratory infections
- Individuals with a history of smoking or exposure to carcinogens
- Patients with suspected or confirmed lung cancer needing treatment guidance
- Individuals requiring monitoring of treatment response or disease progression
Significant Benefits of the Oncomine Lung cfTNA Cancer Panel
This advanced genetic testing offers numerous advantages for lung cancer management:
- Non-Invasive Procedure: Requires only a simple blood draw, eliminating the risks associated with tissue biopsies
- Comprehensive Genetic Profiling: Analyzes multiple biomarkers simultaneously for complete molecular characterization
- Personalized Treatment Planning: Enables selection of targeted therapies based on specific genetic mutations
- Early Detection Capability: Can detect cancer-associated genetic changes before traditional methods
- Treatment Monitoring: Allows for ongoing assessment of treatment effectiveness and disease progression
- Reduced Healthcare Costs: Helps avoid ineffective treatments and associated side effects
Understanding Your Test Results
Your Oncomine Lung cfTNA Cancer Panel results will provide detailed information about detected genetic mutations and their clinical significance:
- Positive Results: Indicate the presence of specific genetic mutations that may guide targeted therapy selection
- Negative Results: Suggest absence of detectable mutations in the analyzed genes
- Variant of Unknown Significance: May identify genetic changes whose clinical relevance is not yet established
- Quantitative Data: Provides information about mutation abundance, which can help monitor treatment response
It’s essential to discuss your results with your healthcare provider, who will interpret them in the context of your overall health status, symptoms, and other diagnostic findings. Results are typically available within 2-3 weeks from sample collection.
Test Pricing Information
| Test Name | Discount Price | Regular Price |
|---|---|---|
| Oncomine Lung cfTNA Cancer Panel | $1312 USD | $1750 USD |
Nationwide Accessibility
We have branches across the United States, making the Oncomine Lung cfTNA Cancer Panel accessible to patients in all major cities including New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, and San Jose. Our network of certified healthcare facilities ensures convenient access to this advanced genetic testing technology.
Take Action for Your Health
Don’t wait to get the comprehensive genetic information you need for optimal lung cancer management. The Oncomine Lung cfTNA Cancer Panel provides critical insights that can guide your treatment journey and improve outcomes.
Book your test today by calling +1(267) 388-9828 or visiting our nearest location. Our genetic counselors and healthcare professionals are ready to assist you with scheduling, answer your questions, and provide the support you need throughout the testing process.
Note: This test requires a doctor’s prescription. Prescription requirements do not apply to surgery and pregnancy cases or individuals planning to travel abroad.
